Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population
Launched by ABIONIC SA · May 27, 2020
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male or female, aged ≥ 18 years.
- • 2. Apparently healthy as determined by a subject questionnaire.
- Exclusion Criteria:
- 1) Current diagnosis, or history, of any underlying major medical condition determined by the investigator, including but not limited to:
- • 1. Heart disease
- • 2. Stroke
- • 3. Renal disease
- • 4. Liver disease
- • 5. Pancreatic disease
- • 6. Chronic obstructive pulmonary disorder
- • 7. Bleeding disorders
- • 8. Hypercalcitoninemia
- • 9. HIV AIDS
- • 10. Receiving antibiotic therapy
- • 11. Suspected infection
- • 12. Immunosuppression
- • 2) Underwent procedures related to sepsis, or diagnosed with sepsis, within the last 12 months.
- • 3) Current diagnosis of uncontrolled hypertension, hypotension, or diabetes.
- • 4) Diagnosis of bacterial, fungal, or malaria infection within the last 3 months that required antimicrobial treatment.
- • 5 )Experienced severe trauma, surgery, cardiac shock, or severe burn within the previous 3 months requiring medical care.
- • 6) Current diagnosis of cancer within the last 12 months.
- • 7) Received immunotherapy to stimulate or inhibit cytokines within the last 12 months.
- • 8) Hospitalization for more than 24 hours within the last 3 months.
- • 9) Reported as currently pregnant or nursing a child
- • 10) Unable or unwilling to provide the required blood sample for testing.
- • 11) Any other criteria that, in the opinion of the investigator, would render the participant unsuitable for inclusion in the trial.
About Abionic Sa
Abionic SA is an innovative biotechnology company specializing in the development of rapid diagnostic tests that leverage advanced nanotechnology to improve patient care. Headquartered in Switzerland, Abionic focuses on creating efficient and cost-effective solutions for the early detection of critical health conditions, enabling timely medical interventions. With a commitment to enhancing diagnostic accuracy and accessibility, the company aims to transform the landscape of point-of-care testing, ultimately contributing to better health outcomes worldwide. Through rigorous clinical trials and collaborations, Abionic is dedicated to advancing its pioneering technologies in the healthcare sector.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toledo, Ohio, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials